Introduction
Paroxetine is a phenylpiperidine compound ( Figure 1 ) which has been shown, in vitro and in animals, to be a selective 5-hydroxytryptamine (5-HT) uptake inhibitor (Lassen, 1974) . Early clinical studies have indicated that it is an effective antidepressant with few side effects (Borup et al., 1982) .
This study was designed to investigate the influence of paroxetine, compared with amitriptyline, on the re-uptake of noradrenaline at the neuronal storage sites using the tyramine pressor response test (Ghose et al., 1975) and to determine if it possesses anti-cholinergic or sedative properties in healthy volunteers.
Methods
Twelve healthy non-smoking male subjects aged between 19-22 years and weighing 68.8 kg (± 9 .2) participated in the studies which were double-blind, randomized and of cross-over design. The studies were approved by the local ethics committee and written informed consent was obtained from the volunteers.
In the first study, six subjects received, at weekly intervals, paroxetine 30 mg, amitriptyline 50 mg, or placebo tablets. No other medication was taken. In the second study, seven subjects took either oral paroxetine 30 mg daily for 10 days followed by placebo tablets, or vice versa, the treatment schedules being separated by at least 1 week. Five subjects completed the studies while two withdrew during paroxetine treatment, one for a flu-like illness and one for undefined reasons.
On the test days, subjects attended the department after an overnight fast, rested supine on a couch whilst an indwelling cannula was inserted in a forearm vein and connected to a sterile 3-way stopcock. After 30 min rest, the following measurements were recorded: 1. Salivary volume collected over 5 min (unstimulated). 2. Visual analogue rating scales for alertness. 3. Tyramine pressor response test (TPRT) as described by Ghose et al. (1975 After establishing baseline recordings, treatments were taken with 100 ml water. In the single-dosing study, measurements 1 and 2 were recorded hourly for 3 h while TPRT was repeated after 3 h. In the repeated dosing study, measurements 1 and 3 were performed before taking the treatment and 3 h after dosing on day 1 and day 10 of the study.
Tyramine-dose/pressor response curves were plotted on a semi-log scale and T30s (the doses of tyramine that produced a 30 mm Hg rise in systolic blood pressure) were calculated. The tyramine dose-ratios were derived as follows:
T30 after treatment/i30 before treatment Analysis of variance was performed on log tyramine dose by the method of Barker et al. (1982) for the repeated dose study, and using the statistical package GLIM to fit volunteer and order effects on the single dose study. Wilcoxon test was used for alertness and salivary volume.
Results and Discussion
No significant change in the tyramine pressor response was detected following single and repeated dosing of paroxetine compared with placebo (Tables 1 and 2 ). Single doses of amitriptyline, on the other hand, produced a significant increase in the T30 and the tyramine dose ratio (P < 0.05) compared with both placebo and paroxetine (Table 1) .
No significant changes in salivary volume and degree of alertness were seen following single doses of paroxetine compared with placebo. In contrast single doses of amitriptyline produced a significant reduction (P < 0.05) in overall mean salivary volume and degree of alertness (-1.3 ± 0.5 (s.e. mean) ml/5 min, and -2.6 ± 0.9 (s.e. mean) mm on analogue scales respectively). Table 2 Tyramine dose ratios (natural log) in the repeated dose study. The value for day 10 is: log (T30 on day 10 after treatment/Day 1 before treatment) 
